Project Grant R01CA303979
Award Date 7/2/26
Completion Date 6/30/31
Dollars Obligated $707K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $716,521 to Sloan-Kettering Institute for Cancer Research on August 25, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cells for treating small cell lung cancer (SCLC). The research initiative addresses a critical clinical need, as SCLC currently demonstrates...
- Federal Grant Award Summary Seattle Children's Research Institute received a $470,759 Project Grant from the National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) effective September 1, 2025 through August 31, 2027. The award supports development of an innovative CAR-T (Chimeric Antigen Receptor T-cell) immunotherapy platform designed to overcome T-cell exhaustion in solid tumor treatment, specifically targeting hepatocellular carcinoma patients. The research deliverables...
- Federal Grant Award Summary Western University of Health Sciences received a $429,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2025, through June 30, 2028. The award funds the development and optimization of dual chimeric antigen receptor natural killer (CAR-NK) cells engineered to specifically target acute myeloid leukemia (AML) cells with human leukocyte antigen (HLA)-DR loss. The research...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $533,245 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026 through May 30, 2031. The project investigates protein glutathionylation as a mechanism essential for leukemia-initiating cell (LIC) survival in acute myeloid leukemia (AML). The research aims to develop therapeutic strategies targeting mitochondrial...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $156,000 to The Regents of the University of Colorado (University of Colorado-Denver) under the Cancer Biology Research program (CFDA 93.396) for a two-year project period spanning April 1, 2026, through March 31, 2028. The award funds optimization of preclinical research models for adamantinomatous craniopharyngioma (ACP), a rare and highly morbid pediatric brain tumor. The primary deliverables include refinement...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $415,257 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 3, 2025, with completion targeted for June 30, 2027. This research initiative focuses on developing novel chimeric antigen receptor (CAR) T-cell therapies by harnessing B cells from patients following stem cell transplantation for hematological malignancies...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Beckman Research Institute of the City of Hope a $517,090 Project Grant under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, to investigate the role and biological function of a novel signature gene designated AL021978.1 (A978) in Philadelphia chromosome (PH)-positive and PH-like B-cell acute lymphoblastic leukemia (B-ALL). The research aims to address high-risk leukemia subtypes with survival...
- Federal Project Grant Summary Funding Agency & Program: The National Cancer Institute (NCI) awarded this Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, with a total federal obligation of $683,698 through May 31, 2031. The award supports preclinical research and development of a novel therapeutic strategy for high-risk B-cell acute lymphoblastic leukemia (B-ALL). Products and Services Delivered: Cincinnati Children's Hospital Medical Center, in...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Washington University a $399,829 Project Grant on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research on chimeric antigen receptor (CAR) dendritic cell (DC) immunotherapy for solid tumors. The project, which runs through April 30, 2028, will deliver mechanistic characterization and optimization of a novel DC-based therapeutic platform called AB7H3-TLR4 CAR-DCs—engineered...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...